Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

1
Last update : 20/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Checkpoint inhibitor-induced sarcoid choroidal granulomas.
American journal of ophthalmology case reports 2020 Jun;18;100652 2020 Jun
[Nivolumab and sarcoid reaction in lung cancer treatment].
Revue des maladies respiratoires 2019 Feb;36;230-232 2019 Feb
Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma.
Clinical nuclear medicine 2017 Sep;42;728-729 2017 Sep
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Mar;35;709-717 2017 Mar
Pulmonary sarcoid-like granulomatosis induced by nivolumab.
The British journal of dermatology 2017 Apr;176;1060-1063 2017 Apr
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Chest 2016 May;149;e133-6 2016 May
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013;; 2013
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
The New England journal of medicine 2012 Jun 28;366;2455-65 2012 Jun 28

Powered by

  • ^
  • Contact
  • Cookies
  • About